Literature DB >> 28748264

[Zoledronate-induced panuveitis].

A Bergua1, B Hohberger2.   

Abstract

Zoledronate-induced (Aclasta®) uveitis is a rare iatrogen-induced inflammation of ocular structures, which can result in substantial morphological and functional limitations. This case report describes the clinical course of a female patient with zoledronate-induced panuveitis. Additionally, the diagnostic procedure, therapy and follow-up are presented.

Entities:  

Keywords:  Bisphosphonate; Iatrogen induced; Panuveitis; Uveitis; Zoledronate

Mesh：

Substances：

Year:  2018        PMID： 28748264     DOI： 10.1007/s00347-017-0538-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  13 in total

1.  Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial.

Authors:  D V Patel; M Bolland; Z Nisa; F Al-Abuwsi; M Singh; A Horne; I R Reid; C N J McGhee
Journal:  Osteoporos Int       Date:  2014-09-04       Impact factor: 4.507

2.  The incidence of acute anterior uveitis after intravenous zoledronate.

Authors:  Dipika V Patel; Anne Horne; Meaghan House; Ian R Reid; Charles N J McGhee
Journal:  Ophthalmology       Date:  2013-01-03       Impact factor: 12.079

Review 3.  Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review.

Authors:  C Böni; H Kordic; K Chaloupka
Journal:  Klin Monbl Augenheilkd       Date:  2013-04-29       Impact factor: 0.700

4.  Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells.

Authors:  A Bringmann; S M Schmidt; M M Weck; K M Brauer; K von Schwarzenberg; D Werth; F Grünebach; P Brossart
Journal:  Leukemia       Date:  2007-02-15       Impact factor: 11.528

Review 5.  Bisphosphonate-associated orbital inflammation--a case report and review.

Authors:  Jared D Peterson; Edward H Bedrossian
Journal:  Orbit       Date:  2012-04

6.  Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.

Authors:  Dustin D French; Curtis E Margo
Journal:  Retina       Date:  2008-06       Impact factor: 4.256

7.  Pamidronate disodium and possible ocular adverse drug reactions.

Authors:  V Macarol; F T Fraunfelder
Journal:  Am J Ophthalmol       Date:  1994-08-15       Impact factor: 5.258

8.  Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.

Authors:  D H Schweitzer; M Oostendorp-van de Ruit; G Van der Pluijm; C W Löwik; S E Papapoulos
Journal:  J Bone Miner Res       Date:  1995-06       Impact factor: 6.741

Review 9.  Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review.

Authors:  Adnan Pirbhai; Saul N Rajak; Lucy A Goold; Thomas S Cunneen; Geoff Wilcsek; Peter Martin; Igal Leibovitch; Dinesh Selva
Journal:  Orbit       Date:  2015-11-05

10.  Tamoxifen retinopathy: a case report.

Authors:  Lingling Wang; Heng Miao; Xiaoxin Li
Journal:  Springerplus       Date:  2015-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.